Emixustat盐酸盐治疗年龄相关性黄斑变性继发地图样萎缩的随机临床试验
这项多中心、随机、双盲、安慰剂对照的2b/3期临床试验纳入508例年龄相关性黄斑变性继发地图样萎缩患者,随机接受emixustat 2.5 mg、5 mg、10 mg或安慰剂口服每日一次治疗24个月。结果显示emixustat各剂量组地图样萎缩年增长率与安慰剂组相似(emixustat:1.69至1.84 mm²/年;安慰剂:1.69 mm²/年;P ≥ 0.81),未降低地图样萎缩增长率;最常见不良事件为暗适应延迟(55%)、色视症(18%)、视觉损害(15%)和红视症(15%)。
要点
- Emixustat各剂量组地图样萎缩年增长率与安慰剂组相似,未降低增长率。
- 基线低亮度缺损≥20字母者24个月内地图形萎缩增长更快。
- 最常见不良事件为暗适应延迟(55%)、色视症(18%)、视觉损害(15%)和红视症(15%)。
核心结论
- Emixustat未降低年龄相关性黄斑变性继发地图样萎缩的增长率。
- 最常见不良事件为眼部不良事件,可能与该药作用机制相关。
- 该研究2年数据增进了对地图样萎缩自然病史及影响其增长率的基线特征的理解。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的2b/3期临床试验。
- 纳入年龄相关性黄斑变性继发地图样萎缩、视力评分至少35字母、地图样萎缩总面积1.25至18 mm²的患者。
- 508例受试者按1:1:1:1随机接受emixustat 2.5 mg、5 mg、10 mg或安慰剂口服每日一次治疗24个月。
- 320例完成研究。
主要发现
- emixustat组地图样萎缩年增长率为1.69至1.84 mm²/年,安慰剂组为1.69 mm²/年,P ≥ 0.81。
- 正常亮度最佳矫正视力变化在各组间相当。
- 基线低亮度缺损≥20字母的受试者24个月内地图形萎缩增长更快。
- 所测年龄相关性黄斑变性相关单核苷酸多态性的风险等位基因状态与地图样萎缩增长率之间未观察到关系。
- emixustat治疗受试者最常见不良事件为暗适应延迟(55%)、色视症(18%)、视觉损害(15%)和红视症(15%)。
关键数值与推荐
- 主要疗效终点为研究眼地图样萎缩总面积的年平均增长率,由中心阅读中心使用眼底自发荧光图像测量。
- 次要疗效终点为正常亮度最佳矫正视力较基线的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether emixustat hydrochloride (emixustat) reduces the rate of enlargement of geographic atrophy (GA) compared with placebo in subjects with age-related macular degeneration (AMD) and to evaluate the safety and tolerability of emixustat over 24 months of treatment. DESIGN: Multicenter, randomized, double-masked, placebo-controlled, phase 2b/3 clinical trial. PARTICIPANTS: Patients with GA secondary to AMD, a visual acuity score of at least 35 letters, and GA with a total area of 1.25 to 18 mm2 were enrolled. METHODS: Subjects were randomized (1:1:1:1) to emixustat 2.5 mg, 5 mg, 10 mg, or placebo, administered orally once daily for 24 months. Visits included screening, baseline, and months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, and 25. MAIN OUTCOME MEASURES: The primary efficacy end point was the mean annual growth rate of total GA area in the study eye, as measured by a central reading center using fundus autofluorescence (FAF) images. The change from baseline in normal luminance best-corrected visual acuity (NL-BCVA) was a secondary efficacy end point. RESULTS: Of 508 randomized subjects, 320 completed the study. Demographics and baseline characteristics were comparable between treatment groups. On average, GA lesions in the study eye grew at a similar rate in each group (emixustat: 1.69 to 1.84 mm2/year; placebo: 1.69 mm2/year; P ≥ 0.81). Changes in NL-BCVA were also comparable between groups. Subjects with a larger low luminance deficit (LLD) at baseline (≥20 letters) demonstrated a more rapid growth of GA over 24 months. No relationship was observed between the risk-allele status of the AMD-associated single-nucleotide polymorphisms tested and the growth rate of GA. The most common adverse events in emixustat-treated subjects were delayed dark adaptation (55%), chromatopsia (18%), visual impairment (15%), and erythropsia (15%). CONCLUSIONS: Emixustat did not reduce the growth rate of GA in AMD. The most common adverse events were ocular in nature and likely related to the drug's mechanism of action. Data gained from this study over a 2-year period add to the understanding of the natural history of GA and the baseline characteristics affecting the growth rate of GA.
引用
- Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial. Ophthalmology. 2018. PMID: 29716784. doi:10.1016/j.ophtha.2018.03.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。